Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 5, 2017, Pages 675-683

  Di Poto, Cristina ^a   Ferrarini, Alessia ^a   Zhao, Yi ^b   Varghese, Rency S ^a   Tu, Chao ^a   Zuo, Yiming ^a   Wang, Minkun ^a   Ranjbar, Mohammad R Nezami ^a   Luo, Yue ^a   Zhang, Chi ^a   Desai, Chirag S ^c   Shetty, Kirti ^d   Tadesse, Mahlet G ^e   Ressom, Habtom W ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPANOL; ALPHA FETOPROTEIN; CREATININE; GLUCOSAMINE; GLUTAMIC ACID; GLYCINE; ISOLEUCINE; LAURIC ACID; LINOLEIC ACID; PHOSPHATE; PHOSPHORIC ACID; PYROGLUTAMIC ACID; SORBOSE; TAGATOSE; TUMOR MARKER; VALINE;

ADULT; ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SUPPORT VECTOR MACHINE; AGED; BLOOD; LIVER TUMOR; MIDDLE AGED; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLOMICS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 85019203848     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0366     Document Type: Article

References (25)

1. Torre LA, Bray F, Siegel RL, Ferlay J, LortetTieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin 2015;65:87-108.
2. American Cancer Society. Breast cancer in situ. Cancer Facts and Figures 2015. Atlanta, GA: American Cancer Society; 2015
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245-55.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
5. Kim JU, Shariff MI,CrosseyMM, Gomez-Romero M,Holmes E, Cox IJ, et al. Hepatocellular carcinoma: review of disease and tumor biomarkers. World J Hepatol 2016;8:471.
6. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.
7. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-g-carboxy prothrombin and a-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138:493-502.
8. Liesenfeld DB, Habermann N,Owen RW, Scalbert A, Ulrich CM. Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prev 2013;22:2182-201.
9. Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc. Series B (Methodological) 1996:267-88.
10. Ranjbar MRN, Luo Y, Di Poto C, Varghese RS, Ferrarini A, Zhang C, et al. GC-MS based plasma metabolomics for identification of candidate biomarkers for hepatocellular carcinoma in Egyptian cohort. PLoS ONE 2015;10:e0127299.
11. Stein SE. An integrated method for spectrum extraction and compound identification from gas chromatography/mass spectrometry data. J AmSoc Mass Spectrometry 1999;10:770-81.
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc. Series B (Methodological) 1995;57:289-300.
13. Friedman J, Hastie T, Tibshirani R. Sparse inverse covariance estimation with the graphical lasso. Biostatistics 2008;9:432-41.
14. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and regression trees. Boca Raton, FL: CRC Press; 1984.
15. Posma JM, Robinette SL, Holmes E, Nicholson JK. MetaboNetworks, an interactive Matlab-based toolbox for creating, customizing and exploring sub-networks from KEGG. Bioinformatics 2014;30: 893-5.
16. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3. 0-making metabolomics more meaningful. Nucleic Acids Res 2015; 43:W251-7.
17. Armitage EG, Kotze HL, Allwood JW, Dunn WB, Goodacre R, Williams KJ. Metabolic profiling reveals potential metabolic markers associated with Hypoxia Inducible Factor-mediated signalling in hypoxic cancer cells. Sci Rep 2015;5:15649.
18. O'Connell TM. The complex role of branched chain amino acids in diabetes and cancer. Metabolites 2013;3:931-45.
19. Tom A, Nair KS. Assessment of branched-chain amino Acid status and potential for biomarkers. J Nutr 2006;136:324S-30S.
20. Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD. Leucine supplementation differentially enhances pancreatic cancer growth in lean and overweight mice. Cancer Metab 2014;2:6.
21. Lin X, Zhang Y, Ye G, Li X, Yin P, Ruan Q, et al. Classification and differential metabolite discovery of liver diseases based on plasma metabolic profiling and support vector machines. J Separation Sci 2011; 34:3029-36.
22. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 2015;13:2140-51.
23. Dam G, Sørensen M, Buhl M, Sandahl TD, Møller N, Ott P, et al. Muscle metabolism and whole blood amino acid profile in patients with liver disease. Scand J Clin Lab Invest 2015;75:674-80.
24. Beyoglu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol 2013;59:842-58.
25. Zhou S, Huang C, Wei Y. Themetabolic switch and its regulation in cancer cells. Sci China Life Sci 2010;53:942-58.